nach oben

05.04.2024 | Neurology and Preclinical Neurological Studies - Original Article

Amantadine use in the French prospective NS-Park cohort

verfasst von: Margherita Fabbri, Vanessa Rousseau, Jean-Christophe Corvol, Agnès Sommet, Florence Tubach, Yann De Rycke, Nathalie Bertille, Yajiththa Selvarasa, Stephanie Carvalho, Véronique Chaigneau, Christine Brefel-Courbon, Fabienne Ory-Magne, Samuel Tessier, Melissa Tir, Matthieu Bereau, Wassilios G. Meissner, Claire Thiriez, Ana Marques, Philippe Remy, Vincent Schneider, Elena Moro, Luc Defebvre, Jean Luc Houeto, Stephane Prange, Alexandre Eusebio, Christian Geny, Solène Frismand, Philippe Damier, Caroline Giordana Reuther, Giovanni Castelnovo, Isabelle Benatru, Anne Doe De Maindreville, Sophie Drapier, David Maltête, Ouhaid Lagha-Boukbiza, Olivier Rascol, for the French N. S.-Park network

Erschienen in: Journal of Neural Transmission

Einloggen, um Zugang zu erhalten

Abstract

Objective

To assess amantadine use and associated factors in the patients with Parkinson’s disease (PD).

Background

Immediate-release amantadine is approved for the treatment of PD and is largely used in clinical practice to treat “levodopa-induced dyskinesia (LIDs). Its use varies according to countries and PD stages. The prospective NS-Park cohort collects features of PD patients followed by 26 French PD Expert Centres.

Methods

Variables used for the analyses included demographics, motor and non-motor PD symptoms and motor complications [motor fluctuations (MFs), LIDs)], antiparkinsonian pharmacological classes and levodopa equivalent daily dose (LEDD). We evaluated: (i) prevalence of amantadine use and compared clinical features of amantadine users vs. non-users (cross-sectional analysis); (ii) factors associated with amantadine initiation (longitudinal analysis); (iii) amantadine effect on LIDs, MFs, apathy, impulse control disorders and freezing of gait (Fog) (longitudinal analysis).

Results

Amantadine use prevalence was 12.6% (1,585/12,542, median dose = 200 mg). Amantadine users were significantly younger, with longer and more severe PD symptoms, greater LEDD and more frequent use of device-aided/surgical treatment. Factors independently associated with amantadine initiation were younger age, longer PD duration, more frequent LIDs, MFs and FoG, higher LEDD and better cognitive function. 9 of the 658 patients on amantadine had stopped it at the following visit, after 12–18 months (1.3%). New users of amantadine presented a higher improvement in LIDs and MF compared to amantadine never users.

Conclusions

About 12% of PD patients within the French NS-Park cohort used amantadine, mostly those with younger age and more severe PD. Amantadine initiation was associated with a subsequent reduction in LIDs and MFs.

Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J (2006) A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 355(9):896–908. https://doi.org/10.1056/NEJMoa060281CrossRefPubMed

Deuschl G, Antonini A, Costa J, Śmiłowska K, Berg D, Corvol JC, Fabbrini G, Ferreira J, Foltynie T, Mir P, Schrag A, Seppi K, Taba P, Ruzicka E, Selikhova M, Henschke N, Villanueva G, Moro E (2022) European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson’s Disease: I. Invasive Therapies. Mov Disord 37(7):1360–1374. https://doi.org/10.1002/mds.29066CrossRefPubMed

Dorsey ER, Sherer T, Okun MS, Bloem BR (2018) The emerging evidence of the Parkinson Pandemic. J Parkinsons Dis 8(s1):S3-s8. https://doi.org/10.3233/jpd-181474CrossRefPubMedPubMedCentral

Elmer LW, Juncos JL, Singer C, Truong DD, Criswell SR, Parashos S, Felt L, Johnson R, Patni R (2018) Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease. CNS Drugs 32(4):387–398. https://doi.org/10.1007/s40263-018-0498-4CrossRefPubMedPubMedCentral

Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C (2018) International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33(8):1248–1266. https://doi.org/10.1002/mds.27372CrossRefPubMed

Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19(9):1020–1028. https://doi.org/10.1002/mds.20213CrossRefPubMed

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170. https://doi.org/10.1002/mds.22340CrossRefPubMed

Hauser RA, Walsh RR, Pahwa R, Chernick D, Formella AE (2021) Amantadine ER (Gocovri(®)) significantly increases ON time without any dyskinesia: pooled analyses from pivotal trials in Parkinson’s disease. Front Neurol 12:645706. https://doi.org/10.3389/fneur.2021.645706CrossRefPubMedPubMedCentral

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184. https://doi.org/10.1136/jnnp.55.3.181CrossRefPubMedPubMedCentral

Kaasinen V, Luo S, Martinez-Martin P, Goetz CG, Stebbins GT (2023) Cross-cultural differences in patient perceptions of dyskinesia in Parkinson’s disease. Mov Disord 38(4):688–692. https://doi.org/10.1002/mds.29335CrossRefPubMed

LeWitt PA (2015) Levodopa therapy for Parkinson’s disease: Pharmacokinetics and pharmacodynamics. Mov Disord 30(1):64–72. https://doi.org/10.1002/mds.26082CrossRefPubMed

Lim SY, Tan AH, Ahmad-Annuar A, Klein C, Tan LCS, Rosales RL, Bhidayasiri R, Wu YR, Shang HF, Evans AH, Pal PK, Hattori N, Tan CT, Jeon B, Tan EK, Lang AE (2019) Parkinson’s disease in the Western Pacific Region. Lancet Neurol 18(9):865–879. https://doi.org/10.1016/s1474-4422(19)30195-4CrossRefPubMed

Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carrière N, Danaila T, Defebvre L, Defer G, Dellapina E, Doé de Maindreville A, Geny C, Maltête D, Meissner WG, Rascol O, Thobois S, Torny F, Tranchant C, Vidailhet M, Corvol JC, Degos B (2019) Descriptive analysis of the French NS-Park registry: towards a nation-wide Parkinson’s disease cohort? Parkinsonism Relat Disord 64:226–234. https://doi.org/10.1016/j.parkreldis.2019.04.012CrossRefPubMed

Orayj K, Lane E (2019) Patterns and determinants of prescribing for Parkinson’s disease: a systematic literature review. Parkinson’s Dis. https://doi.org/10.1155/2019/9237181CrossRef

Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O (2014) Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 82(4):300–307. https://doi.org/10.1212/wnl.0000000000000050CrossRefPubMed

Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, de Bie RMA, Roze E, Miyasaki JM, Hauser RA, Espay AJ, Martello JP, Gurwell JA, Billinghurst L, Sullivan K, Fitts MS, Cothros N, Hall DA, Rafferty M, Hagerbrant L, Hastings T, O’Brien MD, Silsbee H, Gronseth G, Lang AE (2021) Dopaminergic therapy for motor symptoms in early parkinson disease practice guideline summary: a Report of the AAN Guideline Subcommittee. Neurology 97(20):942–957. https://doi.org/10.1212/wnl.0000000000012868CrossRefPubMedPubMedCentral

Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S (2020) Utilization patterns of amantadine in Parkinson’s disease patients enrolled in the French COPARK Study. Drugs Aging 37(3):215–223. https://doi.org/10.1007/s40266-019-00740-2CrossRefPubMed

Rascol O, Fabbri M, Poewe W (2021) Amantadine in the treatment of Parkinson’s disease and other movement disorders. Lancet Neurol 20(12):1048–1056. https://doi.org/10.1016/s1474-4422(21)00249-0CrossRefPubMed

Rascol O, Ory-Magne F, Azulay JP, Defebvre L, Houeto JL, Maltete D, Remy P, Foubert-Samier A, Sommet A, Thalamas C, Thobois S, Corvol JC, Ns-Park/Fcrin N (2023) Decreased occurrence of dyskinesia when combining amantadine to L-DOPA in early parkinson disease (PD): the PREMANDYSK Trial. Mov Disord 38

Rosa MM, Ferreira JJ, Coelho M, Freire R, Sampaio C (2010) Prescribing patterns of antiparkinsonian agents in Europe. Mov Disord 25(8):1053–1060. https://doi.org/10.1002/mds.23038CrossRefPubMed

Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68(3):400–404. https://doi.org/10.1002/ana.22029CrossRefPubMed

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653. https://doi.org/10.1002/mds.23429CrossRefPubMed

Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 50(5):1323–1326. https://doi.org/10.1212/wnl.50.5.1323CrossRefPubMed

Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28(8):1064–1071. https://doi.org/10.1002/mds.25364CrossRefPubMed

Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68(6):963–968. https://doi.org/10.1002/ana.22164CrossRefPubMed

Zhang ZX, Chen H, Chen SD, Shao M, Sun SG, Qu QM, Zhang BR, Liu YM, Xu Q, Wan X, Li L, Wen HB, Chen X, Chen HB, Liu ZG, Wang J, Wang G (2014) Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China. BMC Res Notes 7:65. https://doi.org/10.1186/1756-0500-7-65CrossRefPubMedPubMedCentral

Titel: Amantadine use in the French prospective NS-Park cohort
verfasst von: Margherita Fabbri
Vanessa Rousseau
Jean-Christophe Corvol
Agnès Sommet
Florence Tubach
Yann De Rycke
Nathalie Bertille
Yajiththa Selvarasa
Stephanie Carvalho
Véronique Chaigneau
Christine Brefel-Courbon
Fabienne Ory-Magne
Samuel Tessier
Melissa Tir
Matthieu Bereau
Wassilios G. Meissner
Claire Thiriez
Ana Marques
Philippe Remy
Vincent Schneider
Elena Moro
Luc Defebvre
Jean Luc Houeto
Stephane Prange
Alexandre Eusebio
Christian Geny
Solène Frismand
Philippe Damier
Caroline Giordana Reuther
Giovanni Castelnovo
Isabelle Benatru
Anne Doe De Maindreville
Sophie Drapier
David Maltête
Ouhaid Lagha-Boukbiza
Olivier Rascol
for the French N. S.-Park network
Publikationsdatum: 05.04.2024
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-024-02772-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen